Quick Introductions: Who are we solving this for?

• Project name and brief one-line description of the transfer (product, originator site → target site)?
• Primary sponsor contact name, title, and best contact email/phone?
• What is the primary business trigger behind this transfer? Options: Regulatory filing deadline, Current site capacity limit, Second-source requirement, Licensing/partner transfer, Cost optimization, Other
• Which product category best describes the molecule being transferred? Options: Small molecule (API/tableting/etc.), Biologic (mAb, recombinant protein), Sterile injectable, Combination product, Other/complex biological
• What stage is the product currently at (provide last milestone achieved)? Options: Preclinical / bench-scale, Phase I/II, Phase III, Commercial on-market, Decommissioned/originator legacy

What if we’re underestimating who actually decides?

• Who are the formal decision-makers for selecting a CDMO and signing off on the transfer? List names, titles, and approval limits if known.
• Which functions have veto power or must approve deliverables (select all that apply)? Options: Head of CMC, VP Manufacturing, Quality/QA Head, Regulatory Affairs, Head of Supply Chain, Legal/Contracts, Commercial/Business Unit
• How do decisions typically get escalated (timeline and forum)—email, weekly steering committee, executive approval, other? Options: Weekly steering committee, Ad hoc exec approvals, Formal change control board, Email approvals, Regulatory-driven signoffs
• Tell us about a previous transfer or outsourcing decision that stalled—who stopped it and why?
• Are there external stakeholders (partners, licensors, health authorities) whose approval is mandatory? If so, name them and their expected involvement.
• How confident are you that the right stakeholders are currently engaged? Options: Completely confident, Mostly confident, Somewhat uncertain, Not confident

Are filing dates driving panic or shaping realistic plans?

• What is the target regulatory milestone or filing date we are working toward? Provide specific month/year.
• What type of regulatory submission is expected (select primary)? Options: New drug application (NDA/MAA), Biologics license application (BLA/MAA), CMC supplement, Post-approval change (sNDA/sMAA), Tech transfer for local registration, Other
• How flexible is the filing date if unexpected delays occur? Options: Not at all flexible, Small buffer (weeks), Moderately flexible (months), Fully flexible
• What are the business consequences of missing the filing or submission window? Options: Lost market exclusivity/revenue, Delay in market launch, Supply interruption, Partner contract penalties, Regulatory hold/inspection risk, Other
• Have you previously negotiated filing timeline extensions with regulators for similar transfers? If yes, briefly describe outcome.
• What internal deadline (e.g., procurement, scale-up, clinical supply needs) must align with the filing date?

What evidence will make regulators quietly nod (and what won’t)?

• What specific CMC/regulatory evidence packages do you anticipate needing for this transfer (characterization, comparability, stability, validation)? Select all that apply. Options: Analytical characterization package, Comparability study/data, Process validation protocol and reports, Stability data, Facility and equipment qualification, Sterility/aseptic validation data, Other
• How complete is your current regulatory dossier for the product (attach or summarize key gaps if possible)? Options: Complete and up to date, Mostly complete with minor gaps, Fragmented — significant gaps, No dossier available
• Have you had prior formal interactions with regulators about this change (pre-IND, scientific advice, pre-submission)? Briefly describe their guidance or concerns.
• Which analytical or functional attributes are most likely to trigger regulatory questions (e.g., impurity profiles, potency drift, sterility assurance)?
• What degree of comparability demonstration would your regulatory team expect—head-to-head batches, extended stability, additional characterization, or mechanism-based bridging? Options: Head-to-head comparative batches, In-depth analytical bridging, Extended stability data, Mechanistic justification with limited bridging, Undecided / need guidance
• If regulators ask for additional studies, which of the following would be feasible within your timeline and budget? Options: Additional analytical work, Extra pilot batches, Expanded stability studies, Nonclinical bridging studies, Not feasible

How will you know we’ve succeeded — beyond 'it worked'?

• What are the non-negotiable acceptance criteria for the transfer (e.g., release specs, yield, impurity limits, potency, sterility)? Please list and prioritize.
• Which commercial KPIs must be met post-transfer (select all that apply)? Options: On-time supply, Batch yield targets, Cost-per-dose or per-batch, Regulatory approval without additional queries, Ability to scale beyond forecast, Other
• What tolerance exists for variance vs originator process (e.g., ±% yield, impurity range)? Options: Very tight (must match closely), Moderate tolerance, Functionally-driven tolerance, Undetermined—need to define
• Who will perform the final acceptance of validation/transfer deliverables on your side, and what documentation do they require?
• How do you want success signals reported during execution—dashboard metrics, weekly steering updates, or milestone signoffs? Options: Executive dashboard, Weekly tactical updates, Milestone-based signoffs, Ad hoc as issues arise, Combination
• If a validation batch marginally misses one acceptance criterion but passes all others, what is your preferred escalation/resolution path? Options: Investigate and retest, Accept with justification and controlled release, Run corrective pilot batch, Escalate to steering committee

When things go sideways, who bears the cost and responsibility?

• What are the top three risks you worry will derail this transfer (technical, timeline, regulatory, supply)? List and rank them.
• Which of the following contingency options do you consider acceptable if primary plans fail? Options: Expedite engineering changes, Use bridging supply from originator, Apply for filing extension, Conduct additional comparability studies, Engage alternate CDMO capacity
• How should change control between your team and the CDMO be handled—strict mutual approvals, delegated authority, or hybrid? Options: Mutual approval required, CDMO delegated for non-critical changes, Hybrid with pre-agreed thresholds, Undecided—need recommendation
• What financial or business impacts are unacceptable (e.g., shipment delays > X weeks, revenue loss > $Y, patient interruption)? Please quantify where possible.
• Have you experienced a transfer failure before? What happened, and what was the downstream impact on supply or filings?
• In a worst-case regulatory or validation failure, who would lead remediation and what timeline would you expect for resolution?

How do you prefer to structure governance, milestones, and accountability?

• What engagement model do you prefer for the CDMO relationship? Options: Turnkey transfer with CDMO-led execution, Joint governance with shared responsibilities, Time-and-materials advisory with you leading execution, Outcome-based with fixed milestones
• Which milestone cadence feels right—tight gating around regulatory dates, monthly checkpoints, or sprint-style 2–4 week cycles? Options: Regulatory-driven gating, Monthly steering checkpoints, Bi-weekly sprints, Ad hoc as needed
• How would you like pricing and change control to be managed—fixed price per module, milestone payments, or T&M with caps? Options: Fixed price per module, Milestone-based payments, Time & Materials with not-to-exceed cap, Hybrid
• What governance artifacts must exist before work begins (e.g., RACI, escalation matrix, quality agreement)? Select all required. Options: RACI matrix, Escalation matrix, Quality agreement, Change control procedure, IP/confidentiality terms, Regulatory communication plan
• Who will be the CDMO’s primary counterpart for day-to-day decisions, and who sits at the steering level? Provide names/roles if known.
• What reporting format will give your leadership confidence—concise risk-focused executive summaries or detailed technical logs? Options: Executive risk-focused summary, Detailed technical reports, Both: exec + appendix, Dashboards + alerts

Let’s Start With Where You Are

• Quickly: what best describes why you’re seeking a transfer partner right now? Options: Regulatory filing deadline, Capacity constraint, Second‑source strategy, Licensing/partner replication, Other
• Which product are we talking about? Provide the molecule name, internal code, and current development or commercial stage.
• What type of product platform is this? Options: Small‑molecule, Biologic (mAb/protein), Sterile injectable, ADC, Peptide/oligonucleotide, Other
• Where is the current process originating from? Options: Originator commercial site, Development lab (in‑house), Academic lab or CRO, Partner/licensee site, Other
• Who is your primary internal owner for the transfer (role/title) and the best contact for technical questions?
• What is your target regulatory submission or go‑live timeframe? Options: Within 3 months, 3–6 months, 6–12 months, 12–18 months, More than 18 months, No fixed date

If We Keep Doing What You’re Doing...

• How confident are you that the originator process as currently described will reproduce the same quality and yield at our site without engineering changes? Options: Very confident, Somewhat confident, Uncertain, Not confident at all
• List the main unit operations in the current process (e.g., synthesis steps, purification, filtration, fill‑finish); be as specific as possible.
• Which material attributes are already identified as critical to product quality? Options: Particle size/distribution, Polymorphic form/crystal habit, Salt form, Residual solvents, Assay purity, Stability profile, Protein aggregation/charge variants, Sterility/bioburden, Other
• Which process parameters have been defined as critical (CPPs) in the originator documentation? Options: Temperature, pH, Mixing speed, Hold time, Pressure, Flow rate/flux, Cycle time, None defined, Other
• How often have originator batches shown significant variability or out‑of‑spec results? Options: Never, Rarely (≤1%), Occasionally (1–5%), Regularly (5–15%), Frequently (>15%)
• When variability occurs, what typically changes—yield, impurity profile, process time, or something else? Describe with an example if available.

What’s Hidden in the Details?

• If we had to run the transfer using only what exists in the current document package, how likely are we to hit validation with no surprises? Options: Very likely, Somewhat likely, Uncertain, Very unlikely
• Which of the following documents can you provide immediately? Options: Batch records, SOPs, Analytical methods and validation, Characterization reports, Stability data, Process development reports, Equipment drawings/P&IDs, Raw lab/analytical data, None of the above, Other
• Are analytical methods fully qualified/validated and transferable as‑is? Options: Yes, validated and transferable, Validated but need re‑validation at new site, Partially qualified, No/Not available, Unknown
• How is originator data currently delivered—editable exports (LIMS/CSV), searchable PDFs, scanned images, or proprietary instrument formats? Options: LIMS/extractable data, Excel/CSV, PDFs (searchable), Scanned images/PDFs, Proprietary instrument formats, Mixed/Other
• Which missing document(s) would cause the biggest delay if we had to recreate them (name up to three and why)?
• Who at the originator is the best contact for retrieving missing documentation, and how responsive are they historically?

Where Small Differences Become Big Problems

• What single equipment or material difference between sites would most likely derail a pilot batch?
• How closely does our receiving equipment match the originator on scale, control sophistication, and geometry? Options: Identical, Minor differences (scale/vendor), Significant differences (geometry/control), Completely different platform, Unknown
• Select equipment characteristics that differ or are unknown and could affect transfer (check all that apply). Options: Vessel geometry/mixing, Impeller type/speed, Heat transfer capability, Filter area/flux, Membrane type, Steam/sterilization method, Containment/aseptic setup, Automation/control system, Other
• Are there known material supply differences (excipients, solvents, API source or grade) that could affect performance? Options: No differences, Minor vendor differences, Different grades/grades unknown, Yes — critical differences, Unknown
• Have you characterized API or intermediate material attributes that are sensitive to equipment (e.g., particle size, shear sensitivity, viscosity)? Options: Yes — detailed data available, Some data but gaps exist, No formal characterization, Unknown
• Would custom parts, equipment modifications, or vendor changes be acceptable if required to reproduce the originator process? Options: Yes — open to modifications, Maybe — needs business case, Prefer not to modify equipment, No

What Happens When the Clock Is Ticking?

• If a missed filing window cost you a quarter of projected revenue, how would that change how you prioritize transfer activities and resources? Options: We would accelerate and add resources, We would reprioritize internally, We would accept the delay, Not sure
• Which regulatory agency and filing type are in scope for your timeline? Options: US FDA (IND/ANDA/NDA/BLA), EMA (MAA), PMDA, Other regional agency, Multiple agencies, Not yet defined
• What is the hard regulatory submission or launch date that cannot slip?
• If the transfer takes longer than expected, which consequence would be most damaging for you? Options: Regulatory delay, Lost revenue, Supply disruption, Reputational risk, Other
• How much schedule buffer do you currently have between completion of transfer activities and filing/launch? Options: >6 months, 3–6 months, 1–3 months, <1 month, No buffer
• What contingency plans exist today if validation or stability data extend past your submission window?

Who Will Argue With the Plan?

• Which internal stakeholder is most likely to block a process change at the critical review gate?
• Select stakeholders who will need to sign off on transfer decisions. Options: Head of CMC, VP Manufacturing, Quality Assurance, Regulatory Affairs, Process Science, Supply Chain, Commercial/Business, External partner/originator, Other
• Which single priority tends to drive each stakeholder group’s decisions? Options: Quality, Timeline, Cost, Supply continuity, Other
• How quickly do stakeholders typically make decisions when presented with a technical trade‑off? Options: Immediately (within days), Within 1–2 weeks, Several weeks, Months, Unclear
• Describe a past instance where stakeholder disagreement delayed a transfer—what was the root cause and what ultimately resolved it?
• What governance model would make approvals smoother for you? Options: Steering committee, Empowered single approver, Weekly alignment meetings, Ad‑hoc approvals, Other

Show Me the Pain in Numbers

• If you had to pick one metric that would prove transfer success, which would it be? Options: Yield, Impurity profile, Cycle time throughput, Regulatory acceptance, Other
• What is the typical yield range for the originator batches (give percentage or range)?
• What are your current in‑spec/passing rates for the most critical assays? Options: >99%, 95–99%, 90–95%, 80–90%, <80%, Unknown
• How variable are batch cycle times or throughput between lots? Options: Very consistent (<5% variation), Moderate (5–15%), High (15–30%), Very high (>30%), Unknown
• Have you experienced failed verification/validation batches? If yes, what was the primary failure mode? Options: No failures, Yield‑related, Impurity/out‑of‑spec, Process control deviation, Analytical method failure, Other
• What commercial impact would a 10% drop in yield or a 1‑month delay have on this program?

If We Could Rewind and Improve

• What would you insist we guarantee before you sign off on a transfer plan?
• Define three non‑negotiable acceptance criteria for the transfer (e.g., impurity limits, throughput, stability shelf‑life).
• What level of process characterization would make you comfortable: basic, moderate, or full product‑lifecycle characterization? Options: Basic (operational fit), Moderate (targeted CPPs/CMAs), Full (DoE, robustness, stress‑testing)
• How much change to the originator method are you willing to accept in exchange for a faster or more robust transfer? Options: No change tolerated, Minor optimizations only, Moderate changes with justification, Substantial rework OK if necessary
• Would you be open to conducting a pilot at an intermediate scale before commercial runs? Options: Yes — required, Yes — preferred, Maybe, No
• What level of documentation handover is required for your regulatory submission? Options: Filing‑ready dossiers plus raw data, Summarized reports and validated methods, SOPs and batch records only, Custom — discuss

First Small Steps We Could Take Together

• If we start today, what’s the single highest‑impact thing we could do within 30 days to reduce uncertainty?
• Which samples or materials can you share immediately to accelerate characterization? (select all that apply) Options: Representative drug substance, Drug product (filled), Stability samples, Reference standards, Excipient samples, None available, Other
• Are you willing to execute an NDA or data‑sharing agreement to speed document exchange? Options: Yes — we have a template, Yes — need to prepare, Maybe — needs internal review, No
• What are convenient dates for a two‑hour technical deep‑dive with your process scientists in the next two weeks?
• Who should we include from your team for technical, QA, and regulatory discussions? Please provide name, role, and preferred contact method.
• What would success look like for the first 90 days of working together?

Setting the Table: Quick facts so we start focused

• Which product/program are we assessing today? (molecule name/code, formulation, and current development/commercial stage)
• What specific trigger brought you to consider a transfer now? Options: Upcoming regulatory filing, Capacity constraint at current site, Second-source requirement, Licensing/partner obligation, Quality/validation failure at originator, Other
• How urgent is the timeline that governs this transfer? Options: Immediate — critical within 0–3 months, High — target 3–6 months, Moderate — 6–12 months, Planned — >12 months
• Who at your organization will be the final authority on trade-offs between speed, cost, and regulatory risk? (name/role) Options: Head of CMC, VP Manufacturing, Technical Operations Director, Quality/Regulatory Lead, Project Manager, Cross-functional committee
• On a scale, how complete and reliable is the originator’s process documentation we’d receive? Options: Complete and high confidence, Mostly complete — gaps expected, Fragmentary — several unknowns, Minimal / mostly tacit knowledge

What's the one risk here you’d rather we discovered now than during validation?

• Which of the following risk categories keeps you most concerned today? Options: Technical/process reproducibility, Regulatory/filing timing, Raw material or API supply, Manufacturing capacity/scale-up, Analytical method gaps, Quality system compatibility
• Tell us about any previous transfers or scale-ups for this product (or similar products) that had unexpected failures — what happened and what was the root cause?
• How often do near-miss or out-of-spec events occur in the current originator process (per 100 batches or per year)? Options: Never documented, Rarely (≤1/year), Occasionally (2–5/year), Frequently (>5/year)
• When a process deviation occurred historically, how quickly were you able to diagnose root cause and implement a fix? Options: Within days, Within weeks, Months, Not resolved / recurring
• Which signs or data points would you want us to treat as an early warning during characterization and pilot batches? Options: Yield drop, Impurity profile shift, Critical attribute drift, Longer cycle times, Equipment incompatibility, Analytical method failure

Regulatory time bombs: do you have wiggle room or are we sprinting to a cut-off?

• Which regulatory submissions or windows are driving the schedule (include agency and target date)?
• If a transfer at the receiving site slips past your filing window, what are the realistic regulatory consequences? Options: Miss submission — delayed approval, Need for additional comparability studies, Complete revalidation, Hold on market supply, Unclear — depends on agency feedback
• Which regulatory authorities/jurisdictions must we satisfy for this product? Options: US FDA, EMA, MHRA/UK, PMDA (Japan), ANVISA / Brazil, Other regional authorities
• Have you previously obtained agency feedback on transfer approaches or comparability for this product? If so, what did they require or emphasize?
• How much schedule buffer do you feel is acceptable before the filing risk becomes intolerable? Options: <2 weeks, 2–6 weeks, 6–12 weeks, >12 weeks

Supply chain pinch points — whose shortage ruins our plan first?

• Which critical materials, suppliers, or single-source inputs are essential to your process? Options: Active pharmaceutical ingredient (API), Key intermediates, Excipient(s), Single-use components, Specialized reagents/biologics, Proprietary supply from originator
• What are current lead times and volume limits for those critical inputs? Options: Days–weeks, 1–3 months, 3–6 months, 6+ months, Unknown / variable
• Do you have alternate suppliers qualified or in discussion for any of those critical inputs? Options: Yes — fully qualified, Yes — qualification in progress, Identified but not qualified, No alternates identified
• If a key supplier failed during validation or scale-up, what short-term mitigations could you accept? Options: Temporary scale-down, Bridging batches from originator, Expedited supplier qualification, Formulation or material substitution, Regulatory change notification
• How do supply interruptions emotionally land on your team—do they trigger crisis mode, extended negotiations, or a resigned acceptance? Options: Immediate crisis — escalates to execs, Operational scramble — cross-functional effort, Managed but stressful, We’ve accepted delays as normal

Technical unknowns: which part of the process do you fear will not survive the move?

• Which unit operations or steps have the least characterization data (e.g., sterility hold, chromatography, lyophilization, CQA control)? Options: Upstream/bioreactor, Purification/chromatography, Formulation, Sterile fill/finish, Drying/lyophilization, Analytical/assay methods
• How well-defined are your critical material attributes (CMAs) and critical process parameters (CPPs)? Options: Well-defined and linked to CQAs, Partially defined — gaps exist, Poorly defined / inferred from tacit knowledge, Not defined
• Which analytical methods will require bridging, transfer, or method revalidation at the receiving site? Options: Potency assay, Impurity/related substances, Particle size/aggregate analysis, Sterility/endotoxin, Identity assays, None / unsure
• Do you expect equipment or facility modifications to reproduce the originator’s process (e.g., reactors, filtration skid, isolators)? Please describe or list the types.
• How long has the team been aware of these technical unknowns, and what attempts (if any) have been made to reduce them? Options: Just discovered, Investigated with limited tests, Extensive root-cause work done, Ongoing but unresolved

Show me the money: if things go wrong, how big is the hole?

• If the transfer misses the filing or capacity target, which of these consequences would most likely occur? Options: Revenue delay or loss, Market supply interruption, Regulatory rework/costs, Loss of partner/license value, Reputational damage, Other
• Can you estimate the approximate financial impact of a 3‑month delay (range or best guess)?
• What is the acceptable probability of a major failure (e.g., failed validation batch, major impurity) for moving forward without additional mitigations? Options: <1%, 1–5%, 5–10%, >10%
• What internal or external stakeholders are most exposed financially or reputationally if we hit a major transfer failure? Options: Commercial leadership, R&D/CMC team, Quality and Regulatory, Supply chain/logistics, Partner/licensee, Patients/market
• Beyond dollars, what non-financial consequences worry you most (e.g., patient access, loss of competitive advantage, agency scrutiny)?

If we had a blank check for risk reduction, what would you demand we lock in first?

• Which of these mitigation levers would you prioritize to reduce the most critical risks? Options: Extended characterization & pilot runs, Parallel supplier qualifications, Dedicated engineering for equipment mods, Regulatory engagement/pre-briefing, Contingency inventory from originator, Faster decision governance/committees
• What measurable acceptance criteria would convince you the receiving site is ready (list 3–5 must-have metrics)?
• How do you prefer trade-off decisions to be made under pressure—single accountable owner, cross-functional committee, or pre-agreed escalation path? Options: Single accountable owner, Cross-functional steering committee, Pre-agreed escalation with executive sign-off, Other
• What contingency trigger would you want in place (e.g., failed verification batch, vendor lead-time slip) that would automatically pause scale-up and force a mitigation plan?
• Realistically, which near-term actions do you want our team to take first to reduce the highest-ranked risk? Options: Immediate technical characterization, Rapid supplier audit/backup, Regulatory pre-submission meeting, Equipment gap analysis and quote, Set up a daily risk war-room

• Solution Experience — Pre-Alignment (Prework Required)
• Playbook Mapping — How Our Transfer Playbook Solves Your Problem
• Technical Proof Session — Characterization, CPPs, and Equipment Demonstration
• Regulatory Evidence Mapping & Impact Workshop
• Acceptance Criteria, Milestones & Go/No-Go Confirmation

• Owners for dossier sections and QA/regulatory reviewers are assigned.
• Customer to confirm critical CQAs and prioritization and provide any missing equipment specs or photographs.
• Schedule Technical Proof Session and circulate the agreed gap list and required lab/sample logistics.
• Agree numeric acceptance criteria and measurement methods for key CQAs/CPPs.
• Identify and assign owners for sample provisioning, bench runs, and equipment assessments.
• Review Prioritized CQAs & CPPs
• Align on a finalized characterization/test matrix and timeline required to prove transfer feasibility.
• Seller to produce the detailed characterization test matrix with sample volumes, methods, and timeline.
• Customer to confirm sample availability, chain-of-custody requirements, and any material handling constraints.
• Engineering to prepare preliminary equipment modification scope and high-level cost/time estimate.
• Regulatory Context Recap
• A regulatory evidence matrix is agreed that ties each dossier item to a playbook deliverable and a target date.
• Customer understands and accepts the quantified filing risk if schedule slips occur and approves mitigation priorities.
• Introductions & Objectives
• Seller to deliver the regulatory evidence matrix and a gated filing timeline for review.
• Customer to confirm internal review cycles, sign-off authorities, and target submission dates.
• Regulatory/QA teams to exchange contact lists and required document formats/profile templates.
• Review Agreed Success Metrics & Acceptance Criteria
• Formal customer confirmation of acceptance criteria and go/no-go gates required to proceed.
• Mutual agreement on milestone dates, resource commitments, and governance for execution.
• Clear handoff plan and scheduled kickoff for the Technical Scope stage with assigned owners.
• Seller to produce the final Technical Scope draft (modules, responsibilities, measurable criteria) for signature.
• Customer to provide formal sign-off on acceptance criteria and confirm named resource allocations.
• Schedule Technical Scope kickoff and circulate the governance and change-control templates.
• Customer and seller agree on a single-sentence Current State that precisely describes what is breaking today.
• Quantified consequence (time, cost, regulatory risk) is documented and accepted by both parties.
• A one-sentence Future State (operational outcome) and 3–5 success metrics are agreed.
• Prework/document gaps identified and a short list of required data to run the Solution Experience is finalized.
• Customer to deliver finalized process dossier, prioritized CQAs, equipment spec list, and filing window within X business days.
• Seller to draft and circulate the one-sentence Current State, quantified consequence summary, and proposed Future State for customer confirmation.
• Schedule the Playbook Mapping session and circulate required pre-reads (tailored playbook outline and comparable-case summaries).
• Recap Current State & Consequence
• Customer confirms that each critical failure is mapped to a specific playbook action and accepts the mapping.
• Seller demonstrates credible proof (case metrics) that the playbook reduces similar consequences and timelines.
• Preliminary list of equipment/process gaps is agreed for technical proof work.
• Clear list of outstanding questions or objections captured for the Technical Proof session.
• Seller to deliver the tailored playbook mapping document with embedded comparable-case metrics and initial gap list.
• Map Evidence to Playbook Milestones
• Confirm Milestones, Timeline & Resource Commitments
• Playbook Phase Mapping
• Confirm Prework & Docs
• Characterization & Test Matrix
• Present Technical Proofs (Data / Analog Cases)
• State the Current State (Facilitated)
• Quantify Filing & Business Impact
• Proof Points from Comparable Transfers
• Change Control & Governance Triggers
• Preliminary Equipment Fit & Gap Summary
• Draft Filing Timeline with Gates
• Equipment Modifications & Scale-Up Demonstration
• Quantify the Consequence
• Final Validation — Customer Explicit Approval
• Tie Each Playbook Step to Your Problem
• Define the Future State (Outcomes)
• Confirm Measurement Methods & Acceptance Criteria
• Next Steps & Handoff to Technical Scope
• Assign Regulatory & QA Owners
• Validation Checkpoint
• Agree Success Metrics & Data Needs
• Force Validation — Explicit Customer Confirmation

• Replicate sending-site process at lab scale
• Experimental characterization of critical process parameters
• Analytical method transfer and validation to receiving lab
• Install and qualify process equipment (IQ/OQ/PQ)
• Perform pilot production and engineering runs
• Execute process performance qualification (PPQ) batches
• Qualify cleaning and sanitization procedures
• Sterile fill/finish qualification and media fills
• Environmental monitoring and sterility verification
• Compile technical transfer dossier and batch records
• Prepare regulatory filing packages and validation reports
• Train operators and QC analysts on transferred processes
• Source and qualify critical raw materials and suppliers
• Produce stability batches and generate stability reports

Replicate sending-site process at lab scale

• Is a direct laboratory-scale replication of the sending-site process required as part of the transfer? Options: Yes, No, Partial / Select steps only
• What target lab-scale batch size(s) should we reproduce (e.g., grams, liters)?
• Do you have complete sending-site SOPs, batch records, process flow diagrams and material specs available for replication? Options: All documents available, Partial documentation available, No formal documentation (knowledge transfer only)
• Which material attributes or in-process tests must match the sending site for replication to be considered successful?
• How many lab-scale runs are expected/required to demonstrate reproducibility? Options: 1-2, 3-5, More than 5, Undetermined - advise required
• What is the desired timeline for completing lab-scale replication activities? Options: 2-4 weeks, 1-3 months, 3-6 months, Flexible/No fixed timeline

Experimental characterization of critical process parameters

• Are critical process parameters (CPPs) already defined by the sending site, or do we need to identify them experimentally? Options: CPPs defined by sender, CPPs partly defined, CPP identification required
• What experimental design approach do you expect for CPP characterization? Options: Screening DoE, Full factorial/response surface DoE, One-factor-at-a-time, Exploratory/troubleshooting
• Which parameters are high priority to characterize (e.g., temperature, pH, hold times, agitation, pressure)?
• What level of analytical support (in-house testing, stability-indicating assays, external CRO) is required during characterization? Options: In-house QC, In-house development lab, External CRO, Combination/undecided
• What acceptance criteria or comparability metrics should be applied to characterize acceptable parameter ranges (e.g., potency within X%, impurity limits, CQAs)?
• Who will own statistical/DoE analysis and reporting (customer, CDMO, shared)? Options: CDMO (we deliver report), Customer (we provide data), Joint analysis

Analytical method transfer and validation to receiving lab

• Which analytical methods require transfer/validation (e.g., identity, assay, impurities, biological assays, sterility)? Options: Identity, Assay/potency, Related substances/impurities, Stability-indicating, Bioassay/functional assay, Sterility/endotoxin
• Are validated methods available from the sending site including validation reports and all system suitability criteria? Options: Fully validated and documented, Partially validated, Methods exist only as SOPs, No methods provided
• Do you require method re-development (adaptation to receiving lab equipment) in addition to transfer? Options: Transfer only, Transfer + minor adaptation, Re-development required
• Will reference standards, primary impurities, and validation samples be supplied by the sender or must they be sourced/qualified? Options: Supplied by sender, CDMO to source/qualification required, Mixture
• What level of validation is required (e.g., partial validation, full validation per ICH/USP equivalents)? Options: Partial validation, Full validation, Qualification only (verification)
• What is the target turnaround time for completing method transfer and validation? Options: 2-4 weeks, 1-2 months, 2-4 months, Depends on method complexity

Install and qualify process equipment (IQ/OQ/PQ)

• Which equipment items need installation or modification at the receiving site (list make/model if known)?
• Are as-built drawings, utility requirements (steam, WFI, compressed air) and P&IDs available for the receiving area? Options: Complete set available, Partial documentation, Not available - onsite survey required
• What level of modification is expected for existing equipment (no mods, minor piping/controls, major mechanical mods)? Options: No mods, Minor (fittings, sensors), Moderate (controls, skid interfaces), Major (new vessels/transfer lines)
• Who is responsible for IQ/OQ/PQ protocol creation and execution? Options: CDMO, Customer, Joint
• Are serialization/CFR/21/Annex/other regulatory-specific data capture or MES integrations required during qualification? Options: Yes, No, Undecided
• What acceptance criteria (e.g., equipment performance ranges, throughput, CIP recovery) should be documented in IQ/OQ/PQ?

Perform pilot production and engineering runs

• What are the primary objectives of the pilot/engineering runs (scale-up, process robustness, sampling for methods, process optimization)? Options: Scale-up verification, Robustness testing, Sampling for analytical methods, Troubleshooting/optimization
• What pilot batch size(s) and number of runs are required or expected? Options: Single pilot run (representative), 2-3 runs, 3-6 runs, Undecided - advise required
• Will the CDMO source materials for pilot runs or will customer-supplied batches/raw materials be used? Options: CDMO sourced, Customer supplied, Combination
• Do pilot runs need to follow full GMP (released materials) or can they be conducted under development-grade controls? Options: Full GMP, Development-grade, Mixed (certain steps GMP)
• What in-process and final acceptance criteria will define a successful pilot run (yields, impurity profiles, potency)?
• Are there scheduling constraints tied to regulatory filing windows or material availability that impact pilot run timing? Options: Yes - fixed windows, Some constraints, No

Execute process performance qualification (PPQ) batches

• How many PPQ batches are required by the target regulatory authority or per your internal filing plan? Options: 3, 3 plus 1 stability, 5 or more, Not defined
• Should PPQ runs be executed at full commercial scale or at a defined scale-down model? Options: Full commercial scale, Scaled-down equivalent, Hybrid approach
• What are the predefined acceptance criteria for PPQ (e.g., critical quality attributes, yield, impurity levels)?
• Who will provide QA release and final sign-off for PPQ batches (CDMO QA, Customer QA, Joint)? Options: CDMO QA, Customer QA, Joint approval
• Is concurrent stability initiation on PPQ batches required and, if so, what timepoints are needed for filing? Options: Yes - file-critical timepoints, Yes - full stability program, No - separate stability batches
• What contingency actions should be in scope if a PPQ batch fails acceptance criteria (investigation, repeat batches, filing impact)?

Qualify cleaning and sanitization procedures

• Is the facility single-product or multi-product for the target manufacturing line? Options: Single-product dedicated line, Multi-product shared line
• Are defined worst-case residues and analytical swab/TOC methods available for cleaning validation? Options: Yes - methods available, Methods partially available, No - methods development required
• Which cleaning validation approach do you prefer (e.g., worst-case surrogate, bracketing, rinse/swap)? Options: Worst-case surrogate, Bracketing, Rinse testing, Combined approach
• What acceptance limits should be applied for cleaning validation (e.g., ppm, µg/cm2, toxicological limit)?
• Do you require full cleaning SOP creation, training, and routine monitoring built into qualification? Options: Yes - full package, Partial (protocols only), No
• Who is accountable for post-cleaning release (receiving site QA, customer QA, shared)? Options: Receiving site QA, Customer QA, Shared

Sterile fill/finish qualification and media fills

• Is the product aseptically processed or terminally sterilized? Options: Aseptic/sterile fill, Terminal sterilization, Not sterile product
• What container/closure formats are required (vials, pre-filled syringes, cartridges, ampoules)? Options: Vials, Pre-filled syringes, Cartridges/cartridges, Ampoules, Other
• How many media fill runs are expected for qualification and at what batch sizes? Options: 1-3 runs, 3-5 runs, 5+ runs, Undecided - request guidance
• What environmental classification (ISO5/Grade A/B/C) and personnel qualifications must be demonstrated during fills? Options: ISO5/Grade A, ISO7/Grade B/C, Mixed requirements
• What acceptance criteria should be used for media fills (e.g., zero recovery, alert/action limits)?
• Are specialized isolator/ RABS systems or syringe-filling technologies required and must they be qualified in scope? Options: Yes - isolator/RABS, No - conventional line, Undecided

Environmental monitoring and sterility verification

• Which environmental monitoring methods are required (air sampling, settle plates, surface swabs, active air particle counts)? Options: Air sampling, Settle plates, Surface swabs, Particle counting, Other
• What monitoring frequency and duration are expected pre-production, during, and post-production? Options: Continuous, Daily/Per shift, Per batch, Custom schedule
• Are established alert and action limits available or must limits be proposed and validated? Options: Limits available, Limits partially available, Limits need to be proposed
• Who will review and approve environmental trends and excursions (CDMO QA, customer QA, shared)? Options: CDMO QA, Customer QA, Joint
• Do sterility verification activities require third-party microbiology labs or in-house capabilities? Options: In-house microbiology, External lab (CRO), Combination
• What reporting format and frequency do you expect for EM and sterility reports (daily log, batch report, monthly trending)? Options: Per-batch report, Daily log, Monthly trending, Custom

Compile technical transfer dossier and batch records

• Which dossier components are mandatory for your transfer (SOPs, equipment specs, batch records, validation protocols, stability data)? Options: SOPs, Batch records, Validation protocols/reports, Equipment specs/P&IDs, Analytical methods, Stability data
• What document format and control level is required (eCTD-ready, controlled PDF, paper originals)? Options: eCTD-ready electronic packages, Controlled PDFs in QMS, Paper originals, Combination
• Who will be the dossier approver(s) and final document owner after handover (CDMO document owner, customer document owner, joint)? Options: CDMO owner, Customer owner, Joint ownership
• Are there required metadata or traceability fields for batch records (e.g., lot numbers, operator ID, equipment IDs)? Options: Yes - specific metadata required, No - standard fields sufficient, Undecided
• What is the required delivery timeline for the technical transfer dossier relative to PPQ/commercial start? Options: Before PPQ, At PPQ completion, Before regulatory submission, Other
• Do you require the dossier to include redlines vs. sending-site documents and a traceability matrix mapping differences? Options: Yes, No, Optional

• Statement of Work (SOW)
• Master Services Agreement (MSA)
• Commercial Proposal & Pricing Schedule
• Payment Terms & Invoicing Schedule
• Milestones, Acceptance Criteria & Handoff Conditions
• Change Control Agreement
• Governance & Steering Committee Charter
• Quality Agreement
• Regulatory Responsibility Matrix
• Material Transfer & Supply Agreement (MTA/Supply)
• Capacity Reservation & Resource Commitment
• Intellectual Property & Data Rights Agreement
• Insurance, Indemnity & Liability Terms
• Termination, Suspension & Exit Criteria

• Success Review & Filing Readiness
• Regulatory Handover & Documentation Transfer
• Launch Support & Operational Escalation
• Continuous Improvement & Enhancement Planning
• Quarterly Business Review — Supply, Capacity & Risk

• Establish governance and reporting cadence to track improvement delivery.
• Deliver final eCTD package and traceability matrix to the filing owner and upload to shared repository.
• Document and assign responsibility for any remaining change controls or responses to regulatory questions.
• Grant and verify access permissions for all filing stakeholders to the document repository.
• Support Model & SLA Overview
• Establish a live shared channel and a documented escalation matrix with assigned owners.
• Agree SLAs and triage/RCA expectations for any operational or quality deviations.
• Validate the support model via a simulation and adjust gaps identified.
• Create and invite the agreed roster to the shared CustomerNode channel and publish channel rules.
• Publish the escalation matrix and RACI to the shared repository and notify stakeholders.
• Schedule the first monthly support KPI review and the first incident drill.
• Performance vs Targets
• Capture a prioritized list of improvements that materially reduce risk, cost, or cycle time.
• Agree owners, timelines, and estimated budgets for the top-priority enhancements.
• Welcome & Objectives
• Produce a prioritized enhancement backlog with impact/effort estimates and assigned owners.
• Draft a 90-day roadmap for the top three enhancements with resource requests.
• Integrate approved enhancements into change control and schedule execution windows.
• Supply Performance Review
• Align executives on supply performance and near-term capacity risks.
• Confirm mitigation progress on top risks and decide any required strategic actions.
• Schedule necessary follow-ups (procurement, engineering, regulatory) to resolve capacity or supply gaps.
• Update and circulate the program risk register with mitigation statuses and owners.
• Produce a capacity action plan for any identified constraints with resource estimates.
• Schedule follow-up working sessions for any strategic decisions requiring cross-functional input.
• Confirm whether all success signals are met and the dossier is submission-ready.
• Surface and quantify any residual risks that would block filing and assign mitigations.
• Obtain a clear go/no-go decision and document required conditional actions and owners.
• Agree a firm filing date or an amended timeline with accountable owners.
• Finalize and package regulated submission (eCTD or local equivalent) with signatures and upload to repository.
• Assign owners and deadlines for any conditional open items required before submission.
• Produce a one-page filing readiness memo summarizing decision, outstanding risks, and mitigations.
• Handover Scope & Roles
• Ensure the regulatory filing owner has a complete, traceable, and audit-ready dossier package.
• Confirm data integrity and availability of raw data and audit trails for regulator inspection.
• Agree the process for responding to regulator queries and managing post-submission changes.
• Dossier Module-by-Module Review
• Current State Summary (one-sentence)
• Capacity Utilization & Forecast
• Lessons Learned from Transfer & Validation
• Shared Communication Channel Setup
• Regulatory Pipeline & Upcoming Filings
• Enhancement Backlog & Prioritization
• Success Signals Review
• Traceability Matrix & Batch Linkage
• Escalation Matrix & RACI
• Residual Risk & Impact Assessment
• Issue Triage & RCA Process
• Data Integrity & Audit Trails
• Roadmap, Resourcing & Funding
• Risk Register Review & Mitigation Progress
• Strategic Alignment & Decisions
• Dossier & Filing Checklist Walkthrough
• Rapid Response Simulation
• Regulatory Correspondence & Change Control
• Governance & Reporting for Improvements
• Decision & Conditions
• Reporting Cadence & KPIs
• Handoff Confirmation Checklist
• Next Steps, Owners & Timeline